Physician profile
Anna V Ottaka
NPI 1154613685
$1,293.50
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $192.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $171.20 | 2019 | |
| Novo Nordisk INC | $159.41 | 2019 | |
| Abbvie INC. | $112.46 | 2019 | |
| Ibsa Pharma INC. | $82.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $66.75 | 2019 | |
| Mannkind Corporation | $60.28 | 2019 | |
| Amarin Pharma, INC. | $53.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.79 | 2019 | |
| Merck Sharp & Dohme LLC | $50.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.01 | 2019 | |
| Lilly USA, LLC | $32.35 | 2019 | |
| Corcept Therapeutics | $30.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.38 | 2019 | |
| Therapeuticsmd, INC. | $29.54 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $26.11 | 2019 | |
| Endo Pharmaceuticals INC. | $17.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.81 | 2019 | |
| Seqirus USA INC | $16.81 | 2019 | |
| Antares Pharma, INC. | $15.38 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.56 | 2019 | |
| Pfizer INC. | $13.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ottaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.